Leadership Team

Mr. Rowe has served as the Company’s Chief Executive Officer since August 2022, having first joined the Company in July 2018 as Vice President, Marketing and most recently as the Company’s Chief Operating Officer since January 2021. From February 2016 to June 2018, Mr. Rowe was Senior Director of U.S. and Global Marketing, Ophthalmology at Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), where he was responsible for the United States and international commercialization of glaucoma and ocular hypertension products. From July 2010 until February 2016, Mr. Rowe served in various strategic management roles at Allergan plc (since acquired by AbbVie Inc. (NYSE: ABBV)), most recently as the Head of Corporate Competitive Intelligence, where he supported multiple corporate strategic initiatives as well as strategic planning for the company’s worldwide glaucoma franchise. Mr. Rowe also has held senior marketing roles at Bayer Healthcare Pharmaceuticals Inc., Women First HealthCare, Inc. (a former public company) and senior marketing and health economics roles at Pfizer Inc (NYSE: PFE). Mr. Rowe received an M.S. from Rensselaer Polytechnic Institute and received a B.A. from The State University of New York at Stony Brook.

John Gandolfo has been serving as our Chief Financial Officer and Secretary since December 2017. Mr. Gandolfo has approximately 30 years of experience as a chief financial officer of multiple rapidly growing private and publicly held companies with a primary focus in the life sciences, healthcare and medical device areas. Mr. Gandolfo has had direct responsibility over capital raising, including five public offerings, financial management, mergers and acquisition transactions and SEC reporting throughout his professional career. Prior to joining Eyenovia, Mr. Gandolfo was Chief Financial Officer of Xtant Medical Holdings, Inc. (NYSE: XTNT) from July 2010 through September 2017. Prior to joining Xtant, he served as the Chief Financial Officer for Progenitor Cell Therapy LLC, the global contract development and manufacturing services platform of the Hitachi Chemical Regenerative Medicine Business Sector, represented in the United States by Hitachi Chemical Advanced Therapeutics Solutions, LLC, a manufacturer of stem cell therapies, from January 2009 to June 2010. Prior to joining Progenitor, Mr. Gandolfo served as the Chief Financial Officer of Power Medical Interventions, Inc. (acquired by Covidien Public Limited Company (NYSE: COV, which was in turn acquired by Medtronic Public Limited Company (NYSE: MDT)), a publicly held developer and manufacturer of computerized surgical stapling and cutter systems, from January 2007 to January 2009. Prior to joining Power Medical Interventions, Mr. Gandolfo was the Chief Financial Officer of Bioject Medical Technologies, Inc., a then publicly held supplier of needle-free drug delivery systems to the pharmaceutical and biotechnology industries, from September 2001 to May 2006, and served on the Bioject’s board of directors from September 2006 through May 2007. Prior to joining Bioject, Mr. Gandolfo was the Chief Financial Officer of Capital Access Network, Inc. (now known as CAN Capital, Inc.), a privately held specialty finance company, from 2000 through September 2001, and Xceed Software, Inc. (OTC: EXDW), an Internet consulting firm, from 1999 to 2000. From 1994 to 1999, Mr. Gandolfo was Chief Financial Officer and Chief Operating Officer of Impath, Inc., a then publicly held, cancer-focused healthcare information company. From 1987 through 1994, he was Chief Financial Officer of Medical Resources, Inc., a then publicly held manager of diagnostic imaging centers throughout the United States. Mr. Gandolfo currently serves on the board of directors and audit committee of Odyssey Group International, Inc. (OTC: ODYY). Mr. Gandolfo received his B.A. in business administration from Rutgers University. He is a certified public accountant (inactive status) who began his professional career at Price Waterhouse.

Mr. Kern joined the company in June of 2022 as the Sr. Vice President of Manufacturing and Operations, and was elevated to Chief Operating Officer in December of 2022. Mr. Kern has spent his career helping companies transition from research and development into scaled commercial manufacturing organizations. Over the last 20 years has honed his skills by leading product optimization, supporting regulatory approvals (510K & PMA) and establishing cGMP complaint manufacturing solutions worldwide.

Prior to joining Eyenovia, Mr. Kern held leadership positions in multiple medical device and diagnostic companies including: Hound Labs (a THC breathalyzer), Second Source Medical (a medical device contract manufacturer), BioLux (an orthodontia acceleration device), BAROnova (a removable weight loss implant), Bigfoot Biomedical / Asante Solutions (an insulin delivery device) among others.

Mr. Kern holds a B.S. in Mechanical Engineering Technology from Oregon Institute of Technology.

Enrico Brambilla joined Eyenovia in April 2023 as VP of Product Research and Development. Over the past four years, Enrico served as VP of R&D and Manufacturing at Equinox Ophthalmic. Prior to that, Enrico was Lead Engineer at Breathe Technologies for eight years. Enrico started his engineering career at Electrolux Home Products in Europe prior to moving to ResMed Australia in 2006. He has led product development activities for numerous medical devices, ranging from concept creation, through FDA clearance/approval, and market launch. In addition, he is the holder of numerous international patents.

Greg Bennett joined Eyenovia in January 2018 as the Senior Director of Clinical Operations and was promoted to VP of Clinical Operations in January 2022. From March 2011 until joining Eyenovia he was the Director, Global Clinical Operations for Transcend Medical, Inc. In May 1997, he formed CRR, Inc., a clinical research consulting group, and served as President until March 2011. Prior to CRR, he held clinical research positions at Allergan and Burroughs Wellcome Co. and was an Assistant Professor of Medical Technology at Western Carolina University. During his time in Clinical Research Operations, he has directed numerous studies successfully supporting NDAs and 510(k)s.

Dr. Batheja joined the company in August 2020 as the Executive Director of CMC and was promoted to VP Pharma R&D in June 2021. From August 2016 to August 2020, she held several management positions in Analytical R&D and Quality at Progenics Pharmaceuticals now acquired by Lantheus, where she was involved in the development of the oncology pipeline. From July 2014 to August 2016, she was a Pharmaceutical Consultant working on NDA and ANDA for several different companies. She also held positions at Hi-Tech Pharmacal a subsidiary of Akorn from 2009 to 2014 and was successful in getting approval for several ophthalmic, nasal, and oral drugs.

Dr. Batheja received a Ph.D. from New York Medical College and a post-doctoral fellowship from the National Institute of Cancer.

Mr. Lowe was appointed the Company’s Vice President of Commercial Operations in June of 2021. He brings more than 25 years of executive sales and marketing leadership in pharmaceutical, device and capital equipment sales, clinical applications, and business development at Aerie Pharmaceuticals, Inc., Carl Zeiss Meditec, AcuFocus, Boston Scientific, and INSPIRE Pharmaceuticals, Inc.

Most recently he was the Director of U.S. Sales, followed by Director of Marketing, and executed corporate strategic initiatives as well as strategic planning for the company’s worldwide glaucoma and ocular hypertension franchise.

Mr. Lowe has led multiple commercial launches with novel technologies for the treatment of presbyopia, glaucoma, dry eye, bacterial conjunctivitis, and myopia. He has a proven track record of success in strategic franchise growth, specializing in securing products in the marketplace, and building high performing sales teams in start-up environments.

Mr. Lowe holds a B.Sc. degree in Psychology and Economics from the University of California, Irvine.